Anlotinib combined with temozolomide suppresses glioblastoma growth via mediation of JAK2/STAT3 signaling pathway.

MLA

Xu, Peng, et al. “Anlotinib Combined with Temozolomide Suppresses Glioblastoma Growth via Mediation of JAK2/STAT3 Signaling Pathway.” Cancer Chemotherapy & Pharmacology, vol. 89, no. 2, Feb. 2022, pp. 183–96. EBSCOhost, https://doi.org/10.1007/s00280-021-04380-5.

APA

Xu, P., Wang, H., Pan, H., Chen, J., & Deng, C. (2022). Anlotinib combined with temozolomide suppresses glioblastoma growth via mediation of JAK2/STAT3 signaling pathway. Cancer Chemotherapy & Pharmacology, 89(2), 183–196. https://doi.org/10.1007/s00280-021-04380-5

Chicago

Xu, Peng, Handong Wang, Hao Pan, Jiakai Chen, and Chulei Deng. 2022. “Anlotinib Combined with Temozolomide Suppresses Glioblastoma Growth via Mediation of JAK2/STAT3 Signaling Pathway.” Cancer Chemotherapy & Pharmacology 89 (2): 183–96. doi:10.1007/s00280-021-04380-5.